| P50 | author | Malin Hultcrantz | Q57304529 |
| P2093 | author name string | Magnus Björkholm | |
| | Karin E Smedby | |
| | Paul W Dickman | |
| | Sandra Eloranta | |
| | Jan Samuelsson | |
| | Therese M-L Andersson | |
| | Nurgul Batyrbekova | |
| | Anna Ravn Landtblom | |
| P2860 | cites work | Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function. | Q54254821 |
| | Sorted peripheral blood cells identify CALR mutations in B- and T-lymphocytes | Q61698758 |
| | Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms | Q61860414 |
| | The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders | Q79805830 |
| | Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease | Q87635679 |
| | Tuberculosis and atypical mycobacterial infections in ruxolitinib-treated patients with primary or secondary myelofibrosis or polycythemia vera | Q91031024 |
| | Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis | Q91229014 |
| | B-cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferon-α2, or combination treatment | Q91817678 |
| | Key Role of Inflammation in Myeloproliferative Neoplasms: Instigator of Disease Initiation, Progression. and Symptoms | Q92232334 |
| | Incidence of myeloproliferative neoplasms - trends by subgroup and age in a population-based study in Sweden | Q92578984 |
| | Fedratinib in myelofibrosis | Q94445996 |
| | The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research | Q24644519 |
| | Management of patients with polycythaemia vera: results of a survey among Swedish haematologists | Q28174945 |
| | The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances | Q30249362 |
| | External review and validation of the Swedish national inpatient register | Q33928068 |
| | Autoimmunity and the risk of myeloproliferative neoplasms | Q33952854 |
| | Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect | Q34301568 |
| | Janus kinase inhibitors in dermatology: A systematic review | Q34550745 |
| | Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients | Q34798105 |
| | Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study | Q36157668 |
| | The completeness of the Swedish Cancer Register: a sample survey for year 1998. | Q37259363 |
| | Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries | Q37737483 |
| | Infections in patients with hematologic neoplasms and hematopoietic stem cell transplantation: neutropenia, humoral, and splenic defects | Q37926299 |
| | An immune dysregulation in MPN. | Q38241495 |
| | Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated? | Q38246161 |
| | The new Swedish Prescribed Drug Register--opportunities for pharmacoepidemiological research and experience from the first six months | Q38404794 |
| | Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003. | Q38462046 |
| | Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients | Q38814941 |
| | Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor. | Q38938526 |
| | Registers of the Swedish total population and their use in medical research | Q40105921 |
| | JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms | Q41127061 |
| | JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms | Q41138516 |
| | JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells | Q41160178 |
| | Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study | Q41190830 |
| | The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo | Q43451422 |
| | Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib. | Q46891342 |
| | How close are countries of the WHO European Region to achieving the goal of vaccinating 75% of key risk groups against influenza? Results from national surveys on seasonal influenza vaccination programmes, 2008/2009 to 2014/2015. | Q47233468 |
| | Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis | Q47418268 |
| | The Swedish cause of death register | Q47664991 |
| | Infections associated with ruxolitinib: study in the French Pharmacovigilance database. | Q48230479 |
| | Ruxolitinib-associated infections: A systematic review and meta-analysis. | Q48278553 |
| | Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms: A Population-Based Cohort Study | Q50042051 |
| | Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients. | Q52657272 |
| | Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. | Q52721155 |
| | Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes. | Q53549392 |
| | Chemical JAK inhibitors for the treatment of rheumatoid arthritis. | Q54172510 |
| P921 | main subject | population-based cohort study | Q108562148 |
| P577 | publication date | 2020-06-16 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | Risk of infections in patients with myeloproliferative neoplasms-a population-based cohort study of 8363 patients | |